Clinical trials: TACE
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing liver transplantation.
- Trial name
- SBRTvsTACE (NCT03960008)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- 5 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Lahey Clinic
Chronic Hepatitis B, Hepatocellular Carcinoma
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and chronic hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia.
- Trial name
- NCT01872988
- Testing
- Tenofovir
- Where
- 4 sites in Taiwan
- Volunteers
- 320 people
- Sponsor
- Taichung Veterans General Hospital
Hepatocellular Carcinoma
TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
This study was designed to evaluate the effectiveness and safety of TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
- Trial name
- NCT05550025
- Testing
- camrelizumab& apatinib
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Gastric Cancer
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
This study is a phase II, prospective, single-center, single-arm trial to evaluate the efficacy and safety of the combination of neoadjuvant transcatheter arterial chemoembolization (TACE) and PD-1 antibody Tislelizumab in the…
- Trial name
- NCT04799548
- Testing
- Transcatheter Arterial Chemoembolization, Tislelizumab
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Transarterial Chemoembolization
Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma
The aim of this study was to evaluate whether survival of patients who underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.
- Trial name
- NCT01677468
- Testing
- Intermediate embolization, Complete embolization
- Where
- 3 sites in South Korea
- Volunteers
- 250 people
- Sponsor
- Hallym University Medical Center
Carcinoma, Hepatocellular
TATE Versus TACE in Intermediate Stage HCC
An open label randomized study to compare TATE versus TACE in patients with intermediate stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency ablation.
- Trial name
- TATE (NCT03145558)
- Testing
- Tirapazamine, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Teclison Ltd.
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Primary Liver Cancer
Polyvinyl Alcohol Embolization Microspheres
To evaluate the safety and efficacy of polyvinyl alcohol embolization microspheres developed and manufactured by Shanghai Huihe Medical Technology Co., LTD.
- Trial name
- NCT05770635
- Testing
- Embosphere and chemotherapy drug, Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Shanghai Huihe Medical Technology Co., Ltd
Hepatocellular Carcinoma (HCC), TACE
DEB-TACE vs cTACE in HCC After TIPS
This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional…
- Conditions
- Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
- Trial name
- UPGRADE (NCT07322848)
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 206 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype
TACE against HCC is the standard of care for BCLC stage B patients. In this exploratory study, the investigators assess the efficacy of TACE with or without adagloxad simolenin/OBI-821 treatment in GALNT14 "non-TT" HCC population.
- Trial name
- NCT03608878
- Testing
- adagloxad simolenin/OBI-821, TACE
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma (HCC)
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin
- Trial name
- NCT06644937
- Testing
- TACE combined with Acoradine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Liver Cancer
Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer
The clinical trail of Cinobufacini combined with TACE on primary liver cancer.The trail is randomized controled.Patients are diagnosed primary liver cancer based on pathology or cell biology.They are randomized into 2 groups:both…
- Trial name
- NCT03843229
- Testing
- Cinobufacini injection, Transarterial Chemoembolization(TACE), cinobufacini tablet
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Hepatocellular Carcinoma
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with programmed cell death protein-1 (PD-1) antibody compared with TACE Alone in patients with unresectable…
- Trial name
- NCT03782831
- Testing
- TACE, PD-1 antibody
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
Background: In the treatment of liver cancer, TACE (transarterial chemoembolization) combined with ablation is commonly used. The chemotherapeutic drug iodized oil emulsion prepared by the ultra-stable homogeneous mixture…
- Trial name
- NCT07493070
- Testing
- TACE combined with thermal ablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Medical University Union Hospital
Hepatocellular Carcinoma
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
The purpose of the study is to observe the effect of TACE/HAIC combined with lenvatinib and sintilimab as a neoadjuvant therapy before liver resection in preventing the recurrence in high-risk patients with hepatocellular…
- Trial name
- NCT05250843
- Testing
- TACE/HAIC, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus
It is a prospective and multi-center clinical research in China to compare the efficacy, safety and related impact factors between TACE alone and endovascular brachytherapy combined with stent placement and TACE for HCC with main…
- Trial name
- NCT02971345
- Testing
- Stent and Iodine-125 seed strand implantation, Stent, Iodine-125 seed
- Where
- China
- Volunteers
- 253 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma
A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
At present, for advanced Intrahepatic Cholangiocarcinoma（ICC）, the effect of single treatment is not good.So far, superselective drug-eluting bead transarterial chemoembolization（DEB-TACE） is a good method for the treatment of…
- Trial name
- CCGLC-005 (NCT05236699)
- Testing
- DEB-TACE combined with Surufatinib and Camrelizumab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
To evaluate the time to progression of the combination therapy of Transcatheter Arterial Chemoembolization (TACE) and sorafenib in patients with previously untreated advanced or metastatic hepatocellular carcinoma.
- Trial name
- NCT01170104
- Testing
- Sorafenib, TACE (Transcatheter arterial chemoembolization)
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Chung-Ang University
Cancer, Hepatocellular
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver…
- Trial name
- CheckMate 74W (NCT04340193)
- Testing
- nivolumab, ipilimumab, TACE
- Where
- 107 sites in United States, Australia and 17 more
- Volunteers
- 26 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .
- Trial name
- NCT03510416
- Testing
- Apatinib, TACE
- Volunteers
- 22 people
- Sponsor
- Shanghai Zhongshan Hospital